Welcome to our dedicated page for Zomedica news (Ticker: ZOM), a resource for investors and traders seeking the latest updates and insights on Zomedica stock.
The Zomedica Corp. (ZOM) news page on Stock Titan highlights company announcements, product updates, financial results, and strategic initiatives in equine and companion animal health. Zomedica describes itself as an animal health company offering point-of-care diagnostic and therapeutic device products, and its news flow reflects developments across platforms such as PulseVet, Assisi, TRUFORMA, TRUVIEW, VETGuardian, and VETIGEL.
Readers can find coverage of new product launches and enhancements, including the Assisi Loop Lounge tPEMF therapy bed, expansions of the TRUFORMA diagnostic menu such as the equine progesterone assay and feline cobalamin and folate testing, and updates on the TRUVIEW digital cytology microscope. News items also discuss the VETGuardian Zero Touch monitoring system and how it is being presented to veterinarians through educational webinars.
Zomedica’s releases frequently address distribution and market expansion, such as the expanded agreement with Grovet b.v. in the Netherlands, which broadens access to equine therapeutic devices, VETIGEL hemostatic gel, EquiLoop devices, and the TRUFORMA platform in Europe. Financial news, including quarterly results and commentary on diagnostics, therapeutic devices, consumables, and Development Services, provides insight into segment performance and the company’s stated strategy.
Investors and veterinary professionals can also follow Zomedica’s "Fourth Friday at Four" webinar series and related sessions, where the company offers strategic overviews and product-focused presentations. For anyone tracking ZOM news, this page serves as a centralized view of how Zomedica is advancing its veterinary diagnostic, monitoring, and therapeutic platforms, expanding its intellectual property portfolio, and pursuing international growth.
Waste Energy Corp (OTCQB:WAST) secured USMCA certification and cleared U.S. customs for its patent-pending waste-to-energy conversion technology, with the majority of components en route to its Midland, Texas facility and remaining certified parts due in the first week of January 2026. Installation and commissioning will begin the first week of January, with the system expected to be fully operational by the end of January, positioning the company to enter a revenue generation phase in Q1 2026. The Midland site will convert non-recyclable plastics and tires into fuel, carbon materials, and monetizable environmental assets intended as a repeatable U.S. blueprint.
Zomedica (OTCQB: ZOMDF) announced a collaboration with Prime Video to feature its Assisi and Calmer Canine products in the new romantic comedy Merv, now streaming on Prime Video as of December 11, 2025.
The placement will be supported by coordinated digital, social, and educational campaigns aimed at pet parents, veterinarians, and investors to raise awareness of Zomedica's pet wellness technologies and their real-world applications.
Zomedica (OTCQB:ZOMDF) launched the TRUFORMA Progesterone assay on December 4, 2025, expanding its TRUFORMA point-of-care diagnostic menu into equine reproductive health. The assay delivers immediate, in-clinic progesterone results to support breeding programs, pregnancy monitoring, and therapeutic decisions.
Key points: the TRUFORMA suite now includes ACTH, insulin with automatic dilution, cortisol, and progesterone; the global equine reproductive technologies market was valued at $485M in 2024 and is projected to reach $845M by 2031 (CAGR ~8.1%). The assay is available via myZomedica or customer service.
Zomedica (OTCQB: ZOMDF) announced a special session of its "Fourth Friday at Four" investor webinar to be held on Friday, November 21, 2025 at 4:00 p.m. Eastern Time to provide strategic context for its product platforms, a review of third-quarter 2025 performance, and execution priorities for the remainder of 2025 and entry into 2026. The session will feature prepared remarks followed by a Q&A and a replay will be available after the event. Registration is open at the provided link for investors and stakeholders.
Zomedica (OTCQB: ZOMDF) announced it has earned ISO 13485:2016 certification for its manufacturing and distribution operations in Plymouth, Minnesota and Roswell, Georgia on November 6, 2025. The certification followed an independent audit validating conformity with medical device quality-management requirements across design, production, risk management, servicing, and regulatory compliance.
Management said the certification strengthens quality infrastructure, supports global market readiness and regulatory filings, enhances customer and partner confidence, promotes operational efficiency, and positions Zomedica to scale diagnostics and therapeutics — including potential products for the human health market.
Zomedica (OTCQB:ZOMDF) reported record third quarter results for the period ended September 30, 2025, with revenue up 16% to $8.1 million and a 67% gross margin. Diagnostics revenue rose 51% and new Development Services contributed $0.7M this quarter. Operating expenses fell $0.5M sequentially to $12.0M, driving a lower net loss of $6.1M and an improved Adjusted Non-GAAP EBITDA loss of $3.7M. The company ended the quarter with $54.4M in cash and securities and 979,949,668 shares outstanding.
Zomedica (OTCQB:ZOMDF) launched the Assisi Loop Lounge, a full-body targeted pulsed electromagnetic field (tPEMF) therapy bed for small animals with unlimited uses and a lifetime warranty, positioned for clinic and at-home use for osteoarthritis, chronic pain, post-surgical recovery, hospice care, and travel.
The product is promoted as peer-reviewed and evidence-backed, available through veterinarians, select retailers, and directly from Zomedica. Company highlights include 2024 revenue of $27M (+8% YoY), approximately $59M liquidity as of June 30, 2025, and cited global tPEMF market size of $400–500M in 2025 with an 8–10% CAGR to 2031.
Zomedica (OTCQB:ZOMDF) expanded its distribution agreement with Grovet b.v. to add the TRUFORMA diagnostic platform plus therapeutic products VETIGEL and EquiLoop across the European Union.
The amendment broadens Grovet's equine portfolio, gives transitional support for EU companion-animal entry, and aims to accelerate TRUFORMA adoption in Europe while leveraging Grovet's customer network to drive cross-selling of diagnostic and therapeutic device solutions.
Zomedica (OTCQB:ZOMDF) announced a Fourth Friday at Four webinar on October 24, 2025 at 4:00 p.m. ET to showcase the VETGuardian Zero Touch monitoring platform.
The session will review how the VETGuardian monitor uses radar and imaging technology to capture continuous vital signs—heart rate, respiration, and body temperature—without wires or contact. The release cites a $720 million veterinary monitoring market in 2025, projected to grow at ~8% annually through 2029, and positions VETGuardian as a workflow- and welfare-improving tool that complements Zomedica's diagnostics and therapeutics.
The webinar is offered via live webcast and registration details are available on the company website.
Zomedica (OTCQB:ZOMDF) has expanded its TRUFORMA diagnostic platform by adding feline testing capability to its cobalamin & folate assay, previously only available for canine patients. The multiplexed assay, which combines two critical tests in one, delivers results in under 25 minutes at the point of care.
Originally launched for dogs in early 2024, this first-of-its-kind in-clinic test now addresses the critical need for rapid diagnosis in feline patients with gastrointestinal conditions. According to veterinary experts, this expansion is particularly significant as feline patients with GI disease often deteriorate more rapidly than canine patients, making quick results crucial for timely treatment.
FAQ
What is the current stock price of Zomedica (ZOM)?
What is the market cap of Zomedica (ZOM)?
